Baruch Stern

Baruch Stern, Ph.D, serves as a BioTech Analyst at the Israel Innovation Authority since January 2015 and is a Co-Founder of Novel Therapeutics. As CEO and CSO of 3C Biotech, started in May 2013, Baruch Stern focuses on biotechnological enzymatic solutions aimed at global environmental and sustainability challenges. Previous roles include Scientific Director and CSO at Medgenics, Inc. from 2006 to 2012, where Baruch led the clinical trial submissions and secured significant funding, as well as Project Manager at ProChon Biotech Ltd from 2004 to 2006, directing a team in bio-scaffold development. Baruch’s career began with leadership roles at Biogenics Ltd and Sourasky Medical Center, extending back to postdoctoral work at LTIB/NCI/NIH and academic endeavors at the Open University. Baruch Stern earned a Ph.D. in Biology from Tel Aviv University.